The primary objective of the study is the evaluation of efficacy of a mouthwash cointaining Chlorexidine (CHX) 0.09% + HA + Citrox (test group) on the quality of wound healing and the presence plaque formation and gingival inflammation in the post-surgical phase. Futhermore stains, discolorations and adverse effects will be eventually recorded. Control group will be represented by the use of a CHX 0.12% mouthwash.
More than 20 natural teeth excluding the third molars
Clinical indication for a surgical intervention for the treatment of at least one residual pocket after non-surgical therapy (pocket depth (PD) ≥5mm)
Have a full mouth plaque score (FMPS) <15% before surgery;
Have a full mouth bleeding score (FMBS) <15% before surgery;
Use of medications, such as anti-platelet or anti-coagulant agents, any other concomitant systemic disorder, cardiovascular and diabetes diseases, allergic, infectious diseases and medications affecting periodontal inflammation
Pregnancy or breastfeeding;
Use of medication affecting the healing process;
Assumption of systemic or local antibiotics in the 4 weeks before trial beginning;